- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Conversion Miscalculation Found
Correction to the article “Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis: Pathophysiology, Diagnosis, and the Evolving Treatment Landscape” published in a September 2021 supplement to The American Journal of Managed Care.
Am J Manag Care. 2023;29(10):535. https://doi.org/10.37765/ajmc.2023.89442
In the article “Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis: Pathophysiology, Diagnosis, and the Evolving Treatment Landscape” published in a September 2021 supplement to The American Journal of Managed Care, a conversion miscalculation was found. In the ADVOCATE trial (NCT02994927), which this paper reviews, all glucocorticoids were converted into prednisone-equivalent doses. Recently, a conversion miscalculation was found in the non–study-supplied glucocorticoid dose. There are no changes to the conclusions of the study; however, to be fully transparent the authors suggested correcting the published article. The sentence, “The total prednisone-equivalent dose of oral and IV glucocorticoids was 1349 mg (or about 4 mg/patient/d) in the avacopan group and 3655 mg (or about 12 mg/patient/d) in the prednisone group” should be, “The total mean prednisone-equivalent dose of oral and IV glucocorticoids was 1676 mg (or about 5 mg/patient/d) in the avacopan group and 3847 mg (or about 13 mg/patient/d) in the prednisone group.”
In addition, in Figure 2, the Kaplan-Meier curve lines appeared slightly separated from each other, when they should both begin at 1.0. The figure has been revised to show both curves beginning at 1.0.
The article was corrected online.
REFERENCE
Koening CL, von Hennigs I. Antineutrophil cytoplasmic antibody (ANCA) vasculitis: pathophysiology, diagnosis, and the evolving treatment landscape. Am J Manag Care. 2021;27(suppl 15):S267-S276. doi:10.37765/ajmc.2021.88746
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
February 20th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The February issue features a retrospective by Richard J. Gilfillan, MD, former director of the Center for Medicare and Medicaid Innovation; and Donald M. Berwick, MD, MPP, former administrator of CMS.
Read More
Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans
February 10th 2025This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
Read More
